{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:19:28Z","timestamp":1758759568229,"version":"3.44.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.semarthrit.2023.152272","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:10:01Z","timestamp":1695762601000},"page":"152272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cutaneous immune-related phenomena in patients with inflammatory arthritides treated with biological therapies: Clinical and pathophysiological considerations"],"prefix":"10.1016","volume":"63","author":[{"given":"Aliki I.","family":"Venetsanopoulou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina","family":"Mavridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":false,"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152272_bib0001","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0002","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","article-title":"Alterations in immune function with biologic therapies for autoimmune disease","volume":"137","author":"Her","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152272_bib0003","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00002281-200205000-00002","article-title":"Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases","volume":"14","author":"Criscione","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0004","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed Rep"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1517\/13543784.2014.899351","article-title":"Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis","volume":"23","author":"Braun","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152272_bib0006","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152272_bib0007","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1742-1241.2003.tb10469.x","article-title":"Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis","volume":"57","author":"Kary","year":"2003","journal-title":"International Journal of Clinical Practice"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152272_bib0008","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/14712598.5.9.1245","article-title":"Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis","volume":"5","author":"Teng","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0009","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2147\/DDDT.S105263","article-title":"Secukinumab for rheumatology: development and its potential place in therapy","volume":"10","author":"Koenders","year":"2016","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.semarthrit.2023.152272_bib0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2147\/PPA.S33162","article-title":"Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement","volume":"7","author":"Toussirot","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"10.1016\/j.semarthrit.2023.152272_bib0011","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0012","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"Use of biologics in rheumatoid arthritis: current and emerging paradigms of care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0013","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8316106","article-title":"Optimal Biologic Drugs for the Treatment of Ankylosing Spondylitis: Results from a Network Meta-Analysis and Network Metaregression","volume":"2022","author":"Cao","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0015","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0016","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0017","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.3390\/jcm9041227","article-title":"Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study","volume":"9","author":"Barbieri","year":"2020","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152272_bib0019","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","article-title":"Adverse reactions to biologic agents and their medical management","volume":"10","author":"Boyman","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152272_bib0020","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse side-effects to biological agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0021","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3389\/fphar.2019.00965","article-title":"Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting","volume":"10","author":"de Camargo","year":"2019","journal-title":"Front Pharmacol"},{"issue":"32","key":"10.1016\/j.semarthrit.2023.152272_bib0022","doi-asserted-by":"crossref","first-page":"96","DOI":"10.31138\/mjr.32.2.96","article-title":"Biologic Therapies and Autoimmune Phenomena","volume":"30","author":"Drosos","year":"2021","journal-title":"Mediterr J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0023","article-title":"Biological Therapies: Induced Autoimmune Adverse Manifestations","volume":"11","author":"Drosos","year":"2022","journal-title":"Adv. Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0024","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2017.01.012","article-title":"Adverse Reactions to Biologic Therapy","volume":"37","author":"Patel","year":"2017","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1-2","key":"10.1016\/j.semarthrit.2023.152272_bib0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3121\/cmr.2017.1364","article-title":"Biologic Agent-Associated Cutaneous Adverse Events: A Single Center Experience","volume":"16","author":"Sehgal","year":"2018","journal-title":"Clin Med Res"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0026","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/03009740902922612","article-title":"Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors","volume":"38","author":"Exarchou","year":"2009","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152272_bib0027","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/art.21233","article-title":"Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0028","first-page":"380","article-title":"Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series","volume":"34","author":"Cohen","year":"2007","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0029","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: Systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0030","first-page":"700","article-title":"Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?","volume":"30","author":"Joyau","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0031","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2174\/1573397116666201119151349","article-title":"Cutaneous Autoimmune Phenomena of the Anti-TNFa Biosimilars. Casebased Review","volume":"17","author":"Pelechas","year":"2021","journal-title":"Curr Rheumatol Rev"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152272_bib0032","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ajg.2015.205","article-title":"Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience","volume":"110","author":"Fr\u00e9ling","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0033","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaad.2018.12.018","article-title":"TNF-\u03b1 inhibitor-induced psoriasis: A decade of experience at the Cleveland Clinic","volume":"83","author":"Mazloom","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0034","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1080\/09546630802441234","article-title":"Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases","volume":"20","author":"Ko","year":"2009","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0035","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/tpj.2015.53","article-title":"Paradoxical psoriasiform reactions to anti-TNF\u03b1 drugs are associated with genetic polymorphisms in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2016","journal-title":"Pharmacogenomics J"},{"issue":"5 suppl 1","key":"10.1016\/j.semarthrit.2023.152272_bib0036","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/abd1806-4841.20164456","article-title":"Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis","volume":"91","author":"Vasconcellos","year":"2016","journal-title":"An Bras Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0037","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/DAD.0b013e3181cb3ff7","article-title":"Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-\u03b1 inhibitor therapy. A study of 16 biopsies","volume":"32","author":"Laga","year":"2010","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152272_bib0038","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"11-12","key":"10.1016\/j.semarthrit.2023.152272_bib0039","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0040","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaad.2020.06.081","article-title":"Family history of psoriasis, psychological stressors, and tobacco use are associated with the development of tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: A case-control study","volume":"83","author":"Ya","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0041","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0042","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152272_bib0043","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1002\/art.22811","article-title":"Development of psoriasis after B cell depletion with rituximab","volume":"56","author":"Dass","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152272_bib0044","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2007.080929","article-title":"Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma","volume":"67","author":"Mielke","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0045","first-page":"996","article-title":"Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab","volume":"27","author":"Markatseli","year":"2009","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152272_bib0046","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00002281-200405000-00003","article-title":"B cells as therapeutic targets for rheumatic diseases","volume":"16","author":"Looney","year":"2004","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0047","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/2475530318810851","article-title":"TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management","volume":"4","author":"Li","year":"2019","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0048","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/jdv.13759","article-title":"New-onset vitiligo and progression of pre-existing vitiligo during treatment with biological agents in chronic inflammatory diseases","volume":"31","author":"M\u00e9ry-Bossard","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0049","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000514198","article-title":"Psoriasis, Vitiligo, and Biologic Therapy: Case Report and Narrative Review","volume":"13","author":"Burlando","year":"2021","journal-title":"Case Rep Dermatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.5021\/ad.2015.27.5.620","article-title":"Development of Vitiligo during Treatment with Adalimumab: A Plausible or Paradoxical Response?","volume":"27","author":"Jung","year":"2015","journal-title":"Ann Dermatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0051","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased Risk of Vitiligo Following Anti-Tumor Necrosis Factor Therapy: A 10-Year Population-Based Cohort Study","volume":"138","author":"Bae","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152272_bib0052","doi-asserted-by":"crossref","DOI":"10.5070\/D3263047978","article-title":"A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies","volume":"26","author":"Nguyen","year":"2020","journal-title":"Dermatol Online J"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0053","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152272_bib0054","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1042\/CS20090603","article-title":"Vitiligo, reactive oxygen species and T-cells","volume":"120","author":"Glassman","year":"2011","journal-title":"Clin Sci (Lond)"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/jidsymp.2015.8","article-title":"Oxidative Stress-Induced Chemokine Production Mediates CD8(+) T Cell Skin Trafficking in Vitiligo","volume":"17","author":"Li","year":"2015","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0056","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jaci.2016.10.013","article-title":"Oxidative stress drives CD8+ T-cell skin trafficking in patients with vitiligo through CXCL16 upregulation by activating the unfolded protein response in keratinocytes","volume":"140","author":"Li","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0057","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdin.2020.10.007","article-title":"A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy","volume":"2","author":"Sachdeva","year":"2020","journal-title":"JAAD Int"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0058","doi-asserted-by":"crossref","first-page":"e18907","DOI":"10.1371\/journal.pone.0018907","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0059","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1573397117666211102094330","article-title":"TNF-induced Lupus. A Case-Based Review","volume":"18","author":"Skalkou","year":"2022","journal-title":"Curr Rheumatol Rev"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152272_bib0060","first-page":"889","article-title":"Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNF\u03b1 agents","volume":"10","author":"Dalle Vedove","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0061","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1874312901206010315","article-title":"Anti-Tumor Necrosis Factor-\u03b1 Induced Systemic Lupus Erythematosus","volume":"6","author":"Almoallim","year":"2012","journal-title":"Open Rheumatol J"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102811","article-title":"Skin CD4+ Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus\/subacute cutaneous lupus erythematosus and other skin diseases","volume":"128","author":"Zhao","year":"2022","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.semarthrit.2023.152272_bib0063","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152272_bib0064","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/09612033221095692","article-title":"Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature","volume":"31","author":"Hsieh","year":"2022","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0065","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","article-title":"CRI (Club Rhumatismes et Inflammation). Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France","volume":"73","author":"Saint Marcoux","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.crohns.2012.02.019","article-title":"Reversible Henoch\u2013Sch\u00f6nlein purpura complicating adalimumab therapy","author":"Marques","year":"2012","journal-title":"Journal of Crohn's and Colitis"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152272_bib0067","first-page":"2287","article-title":"Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series","volume":"30","author":"Jarrett","year":"2003","journal-title":"J Rheumatol"},{"issue":"19","key":"10.1016\/j.semarthrit.2023.152272_bib0068","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.3748\/wjg.v21.i19.6082","article-title":"Severe Henoch-Sch\u00f6nlein purpura with infliximab for ulcerative colitis","volume":"21","author":"Song","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"2 Suppl 41","key":"10.1016\/j.semarthrit.2023.152272_bib0069","first-page":"S106","article-title":"Henoch Sch\u00f6nlein purpura following etanercept treatment of rheumatoid arthritis","volume":"24","author":"Duffy","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.rhu.0000239901.34561.5e","article-title":"Henoch-Sch\u00f6nlein purpura after etanercept therapy for psoriasis","volume":"12","author":"Lee","year":"2006","journal-title":"J Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2023.152272_bib0071","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.crohns.2012.02.019","article-title":"Reversible Henoch-Sch\u00f6nlein purpura complicating adalimumab therapy","volume":"6","author":"Marques","year":"2012","journal-title":"J Crohns Colitis"},{"issue":"8","key":"10.1016\/j.semarthrit.2023.152272_bib0072","first-page":"2041","article-title":"Leukocytoclastic vasculitis due to etanercept","volume":"27","author":"Galaria","year":"2000","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0073","first-page":"213","article-title":"Leukocytoclastic vasculitis drug reaction to certolizumab pegol","volume":"30","author":"Woody","year":"2017","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0074","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/jcpt.13117","article-title":"Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis: A case report","volume":"45","author":"Horai","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152272_bib0075","article-title":"Cutaneous Vasculitis During Secukinumab Treatment","volume":"7","author":"da Silva Cendon Duran","year":"2020","journal-title":"Eur J Case Rep Intern Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0076","doi-asserted-by":"crossref","first-page":"adv00077","DOI":"10.2340\/00015555-3435","article-title":"Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis","volume":"100","author":"Chelli","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0077","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.jaip.2019.07.041","article-title":"Rituximab-induced Henoch-Schonlein purpura in a patient with mantle cell lymphoma","volume":"8","author":"Kanchongkittiphon","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.semarthrit.2023.152272_bib0078","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1445-5994.2005.00899.x","article-title":"Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis","volume":"35","author":"Anandacoomarasamy","year":"2005","journal-title":"Intern Med J"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0079","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000051713","article-title":"Rituximab-induced vasculitis","volume":"203","author":"Dereure","year":"2001","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D39XC3222X","article-title":"Erythema nodosum associated with infliximab therapy","volume":"14","author":"Rosen","year":"2008","journal-title":"Dermatol Online J"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0081","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/03009740701288173","article-title":"Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab","volume":"36","author":"Delle Sedie","year":"2007","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0082","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1002\/ibd.21942","article-title":"Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease","volume":"19","author":"Biedermann","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0083","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/1756-185X.12136","article-title":"Erythema nodosum, a \"red flag\" during anti-TNF therapy","volume":"16","author":"Dalmau-Carol\u00e0","year":"2013","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0084","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","article-title":"Alopecia Areata: Review of Epidemiology, Clinical Features, Pathogenesis, and New Treatment Options","volume":"10","author":"Darwin","year":"2018","journal-title":"Int J Trichology"},{"issue":"3","key":"10.1016\/j.semarthrit.2023.152272_bib0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","article-title":"Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management","volume":"61","author":"Zhou","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2023.152272_bib0086","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1001\/archderm.142.12.1653","article-title":"Alopecia Areata During Treatment With Biologic Agents","volume":"142","author":"Tosti","year":"2006","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0087","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2310\/7750.2008.07095","article-title":"Alopecia areata following adalimumab","volume":"13","author":"Kirshen","year":"2009","journal-title":"J Cutan Med Surg"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0088","first-page":"596","article-title":"Alopecia universalis and onychodystrophy during treatment with adalimumab","volume":"33","author":"Youssef","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0089","doi-asserted-by":"crossref","first-page":"529","DOI":"10.4103\/0378-6323.113097","article-title":"Tuneu-Valls A. Alopecia areata in a patient receiving infliximab","volume":"79","author":"Ormaechea-P\u00e9rez","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0090","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s13555-016-0156-z","article-title":"Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies","volume":"6","author":"Udkoff","year":"2016","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0091","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/09273940802596559","article-title":"Alopecia areata during etanercept therapy","volume":"17","author":"Pan","year":"2009","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0092","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/archderm.141.6.759","article-title":"Recurrence of alopecia areata in a patient receiving etanercept injections","volume":"141","author":"Posten","year":"2005","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2023.152272_bib0093","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00296-022-05129-w","article-title":"TNF\u03b1 inhibitor biosimilars associated with alopecia areata. Case-based review","volume":"42","author":"Pelechas","year":"2022","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0094","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jdcr.2019.10.012","article-title":"Ixekizumab-induced alopecia areata","volume":"6","author":"Eldirany","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0095","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000499030","article-title":"Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris","volume":"11","author":"Yajima","year":"2019","journal-title":"Case Rep Dermatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0096","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3315\/jdcr.2010.1041","article-title":"Alopecia areata developing paralell to improvement of psoriasis during ustekinumab therapy","volume":"4","author":"S\u0142owi\u0144ska","year":"2010","journal-title":"J Dermatol Case Rep"},{"issue":"5","key":"10.1016\/j.semarthrit.2023.152272_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103061","article-title":"The current state of knowledge of the immune ecosystem in alopecia areata","volume":"21","author":"Connell","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0098","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/348546","article-title":"Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata","volume":"2013","author":"Ito","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0099","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000069965","article-title":"Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy","volume":"206","author":"Devos","year":"2003","journal-title":"Dermatology"},{"issue":"4","key":"10.1016\/j.semarthrit.2023.152272_bib0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/ard.2007.075663","article-title":"Granuloma annulare induced by anti-tumour necrosis factor therapy","volume":"67","author":"Voulgari","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152272_bib0101","article-title":"Granuloma Annulare in the Setting of Secukinumab","volume":"2018","author":"Clark","year":"2018","journal-title":"Case Rep Dermatol Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2023.152272_bib0102","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00296-018-4212-0","article-title":"Granuloma annulare development in a patient with rheumatoid arthritis treated with tocilizumab: case-based review","volume":"39","author":"Pelechas","year":"2019","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2023.152272_bib0103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40257-021-00636-1","article-title":"Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options","volume":"23","author":"Joshi","year":"2022","journal-title":"Am J Clin Dermatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223001142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:11:54Z","timestamp":1758733914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":103,"alternative-id":["S0049017223001142"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152272","relation":{},"ISSN":["0049-0172"],"issn-type":[{"type":"print","value":"0049-0172"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous immune-related phenomena in patients with inflammatory arthritides treated with biological therapies: Clinical and pathophysiological considerations","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152272"}}